It is very uncertain whether risedronate 5 mg/day changes serious adverse events compared with placebo (very low certainty).
It is very uncertain whether higher changes proportion of participants with ≥ 1 serious adverse events according… compared with lower FiO2 or targets of arterial oxygenation (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Higher‐dose anticoagulants leads to higher adverse events (minor bleeding) compared with lower‐dose anticoagulants (high certainty).
It is very uncertain whether PAE changes major adverse events compared with TURP (very low certainty).
It is very uncertain whether PUL changes major adverse events compared with sham (very low certainty).
It is very uncertain whether PUL changes major adverse events compared with TURP (very low certainty).
It is very uncertain whether aquablation changes major adverse events compared with transurethral resection of the prostate (very low certainty).
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
Naftopidil probably leads to lower sexual adverse events compared with silodosin (alpha‐blocker) (moderate certainty).
Naftopidil showed no clear difference in sexual adverse events compared with tamsulosin (alpha‐blocker) (low certainty).
Silodosin probably leads to higher sexual adverse events compared with tamsulosin (moderate certainty).
Silodosin probably leads to higher sexual adverse events compared with naftopidil (moderate certainty).
Silodosin probably leads to higher sexual adverse events compared with alfuzosin (moderate certainty).
Silodosin probably leads to higher sexual adverse events compared with placebo (moderate certainty).